FierceBiotech

Hyperion Therapeutics’ Glycerol Phenylbutyrate Meets Primary Endpoint in Phase III Pivotal Study in Urea Cycle Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Hyperion Therapeutics, Inc. today announced that the Company’s phase III pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for ...
FierceBiotech

Hyperion Therapeutics Receives FDA Fast Track Designation for Glycerol Phenylbutyrate for the Treatment of Urea Cycle Diso

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Hyperion Therapeutics, Inc. announced today that its investigational compound glycerol phenylbutyrate (HPN-100) has been granted Fast Track Designation ...
Business Insider

Horizon Pharma plc to Present Data on RAVICTI® (glycerol phenylbutyrate) Oral Liquid for Urea Cycle Disorder Patients Aged Two Months to Two Years

DUBLIN, Ireland, March 22, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and ...
Yahoo Finance

Horizon Pharma plc Receives Health Canada Approval for RAVICTI(R) (glycerol phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Two Years of Age ...

DUBLIN, IRELAND--(Marketwired - Mar 21, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and ...